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Abstract
Should whole brain radiation therapy (WBRT) be used as
the sole therapy in patients with newly-diagnosed, surgi-
cally accessible, single brain metastases, compared with
WBRT plus surgical resection, and in what clinical set-
tings?
Target population
This recommendation applies to adults with newly diag-
nosed single brain metastases amenable to surgical resec-
tion; however, the recommendation does not apply to
relatively radiosensitive tumors histologies (i.e., small cell
lung cancer, leukemia, lymphoma, germ cell tumors and
multiple myeloma).
Recommendation
Surgical resection plus WBRT versus WBRT alone
Level 1 Class I evidence supports the use of surgical resection
plus post-operative WBRT, as compared to WBRT alone, in
patients with good performance status (functionally indepen-
dent and spending less than 50% of time in bed) and limited
extra-cranial disease. There is insufﬁcient evidence to make a
recommendation for patients with poor performance scores,
advanced systemic disease, or multiple brain metastases.
If WBRT is used, is there an optimal dosing/fractionation
schedule?
Target population
This recommendation applies to adults with newly diag-
nosed brain metastases.
Recommendation
Level 1 Class I evidence suggests that altered dose/frac-
tionation schedules of WBRT do not result in signiﬁcant
differences in median survival, local control or
neurocognitive outcomes when compared with ‘‘standard’’
WBRT dose/fractionation. (i.e., 30 Gy in 10 fractions or a
biologically effective dose (BED) of 39 Gy10).
If WBRT is used, what impact does tumor histopathology
have on treatment outcomes?
Target population
This recommendation applies to adults with newly diag-
nosed brain metastases.
Recommendation
Given the extremely limited data available, there is insuf-
ﬁcient evidence to support the choice of any particular
dose/fractionation regimen based on histopathology.
The following question is fully addressed in the surgery
guidelinepaperwithinthisseriesbyKalkanisetal.Giventhat
the recommendation resulting from the systematic review of
the literature on this topic is also highly relevant to the dis-
cussion of the role of WBRT in the management of brain
metastases, this recommendation has been included below.
Does the addition of WBRT after surgical resection
improve outcomes when compared with surgical resection
alone?
Target population
This recommendation applies toadultswith newly diagnosed
single brain metastases amenable to surgical resection.
Recommendation
Surgical resection plus WBRT versus surgical resection
alone
Level 1 Surgical resection followed by WBRT represents a
superior treatment modality, in terms of improving tumor
control at the original site of the metastasis and in the brain
overall, when compared to surgical resection alone.
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Rationale
Whole-brain radiation therapy (WBRT) has long been a
standard treatment for patients with brain metastases.
Based on preclinical and observational data, some physi-
cians alter dose fractionation or withhold WBRT based
upon tumor histology.
This paper will systematically review the evidence
available for altered WBRT dose fractionation and the
impact of tumor histopathology on treatment outcomes
when WBRT is used. In addition, this paper will also
systematically review the evidence for the use of surgical
resection plus WBRT compared with WBRT alone in
patients with newly diagnosed, surgically accessible, single
brain metastases. The studies identiﬁed through this process
will be used to make evidence-based recommendations for
the role of WBRT in the management of patients with
newly diagnosed brain metastases.
As WBRT has been a mainstay of the treatment
approach for patients with brain metastases, several other
papers in this guideline series also include comparisons and
recommendations regarding the use of WBRT for this
patient population. Of particular note are the papers by
Kalkanis et al. [1], (surgical resection) and Linskey et al.
[2], (stereotactic radiosurgery) for patients with newly
diagnosed brain metastases.
Methods
Search strategy
The following electronic databases were searched from
1990 to September 2008: MEDLINE
 , Embase
 , Coch-
rane Database of Systematic Reviews, Cochrane Con-
trolled Trials Registry, and Cochrane Database of Abstracts
of Reviews of Effects. A broad search strategy using a
combination of subheadings and text words was employed.
The search strategy is documented in the methodology
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123paper for this guideline series by Robinson et al. [3]R e f -
erence lists of included studies were also reviewed.
Eligibility criteria
(a) For WBRT versus surgical resection plus WBRT
question:
• Published in English with a publication date of
1990 forward.
• Patients with newly diagnosed single brain
metastases.
• Fully published peer-reviewed primary compara-
tive studies (all comparative study designs for
primary data collection included; e.g., randomized
controlled trials (RCTs), non-randomized trials,
cohort studies or case–control studies)
• Study comparisons include: WBRT versus
surgery ? WBRT
• Number of participants with newly diagnosed
brain metastases[5 per study arm
• Baseline information on study participants is
provided by treatment group in studies evaluating
interventions exclusively in patients with newly
diagnosed brain metastases. For studies with
mixed populations (i.e., includes participants with
conditions other than newly diagnosed brain
metastases), baseline information is provided for
the intervention sub-groups of participants with
newly diagnosed brain metastases.
(b) For optimal dosing/fractionation schedule for WBRT
question:
• Published in English.
• Patients with newly diagnosed brain metastases.
• Fully published peer-reviewed primary compara-
tive studies (all comparative study designs for
primary data collection included; e.g., RCT, non-
randomized trials, cohort studies or case–control
studies) for studies published 1990 forward; RCTs
published 1970 forward.
• Study comparisons include: WBRT dose/fraction-
ation schedule 1 versus WBRT dose/fractionation
schedule 2
• Number of participants with newly diagnosed
brain metastases[5 per study arm.
• Baseline information on study participants is
provided by treatment group in studies evaluating
interventions exclusively in patients with newly
diagnosed brain metastases. For studies with
mixed populations (i.e., includes participants with
conditions other than newly diagnosed brain
metastases), baseline information is provided for
the intervention sub-groups of participants with
newly diagnosed brain metastases.
(c) For whether tumor histopathology has an impact on
WBRT treatment outcomes?
• Published in English with a publication date of
1990 forward.
• Patients with newly diagnosed brain metastases.
• Fully published peer-reviewed primary studies (all
study designs for primary data collection
included; e.g., RCT, non-randomized trials, cohort
studies, case–control studies or case series).
• Any study evaluating the outcome(s) of WBRT by
tumor histopathology (or primary tumor type).
• Numberofparticipantswithnewlydiagnosedbrain
metastases [5 per study arm for comparative
studiesand[5overallfornon-comparativestudies.
• For studies evaluating the outcome(s) of WBRT
by histopathology (or primary tumor type) exclu-
sively in patients with newly diagnosed brain
metastases, baseline characteristics are presented
and stratiﬁed by histologic/primary tumor group.
For studies with mixed populations (i.e., includes
participants with conditions other than newly
diagnosed brain metastases), baseline characteris-
tics are presented and stratiﬁed by histologic/
primary tumor group for the sub-group of partic-
ipants with newly diagnosed brain metastases.
Study selection and quality assessment
Two independent reviewers evaluated citations using a pri-
ori criteria for relevance and documented decisions in
standardized forms. Cases of disagreement were resolved
by a third reviewer. The same methodology was used for
full text screening of potentially relevant papers. Studies
which met the eligibility criteria were data extracted by one
reviewer and the extracted information was checked by a
secondreviewer.The PEDroscale [4,5] was used torate the
quality of randomized trials. The quality of comparative
studies using non-randomized designs was evaluated using
eight items selected and modiﬁed from existing scales.
Meta-analyses
Meta-analyses of RCTs were undertaken when sufﬁcient
data for pooling was available for the outcomes of interest.
For the following outcomes, 6 month mortality, overall
survival and neurologic function, the altered WBRT dose/
fractionation schedules were compared to conventional
scheduling. The pooled relative risk (RR) was estimated
using a random-effects model and each RCT was weighted
J Neurooncol (2010) 96:17–32 19
123by the inverse of its variance. Chi-square heterogeneity tests
were used to test for statistical heterogeneity amongst the
RCTs. I
2 was calculated in order to quantify inconsistency
across trials and assess the impact of heterogeneity on the
meta-analysis. Publication bias was evaluated graphically
with funnel plots. All statistical analyses were carried out
using Revman 5.
Evidence classiﬁcation and recommendation levels
Both the quality of the evidence and the strength of the
recommendations were graded according to the American
Association of Neurological Surgeons (AANS)/Congress
of Neurological Surgeons (CNS) criteria. These criteria are
provided in the methodology paper for this guideline series.
Guideline development process
The AANS/CNS convened a multi-disciplinary panel of
clinical experts to develop a series of practice guidelines on
the management of brain metastases based on a systematic
review of the literature conducted in collaboration with
methodologists at the McMaster University Evidence-
based Practice Center.
Scientiﬁc foundation
Overall, 24 primary studies [6–29] and seven companion
papers [30–36] met the eligibility criteria for this system-
atic review (Fig. 1).
Title and Abstract Screening 
n=16,966 
 
Full Text Screening 
n=65 
 
Excluded at Title and  
Abstract 
n=16,901 
Eligible Studies 
n=31 
 
34 Excluded 
No extractable data…………………………………………........1 
No baseline patient data by treatment/ histology group . ……...24 
No treatment comparison of interest………………….........……4 
≤5 patients with brain metastases /group..................................... 3 
Non-comparative study…………………………………….........1 
Unclear treatment interventions….………………………...........1 
 
31 Included 
WBRT vs. WBRT + Surgery…………………………………7 
    [6 unique studies, 1 companion study] 
Different dose/fractionation schedules for WBRT…………..23 
    [17 unique studies, 6 companion studies] 
WBRT by histology…………………………………………..1 
Fig. 1 Flowchart of studies to
ﬁnal number of eligible studies
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123Surgical Resection plus WBRT versus WBRT alone
Seven studies met the eligibility criteria for this treatment
comparison, and of these six were unique and one was a
companion study [6–11, 30]. Three of these studies were
prospective randomized trials [6–8] (Table 1). Given that
the treatment modalities being compared included surgical
resection in only one arm of each trial, all of the RCTs
were non-blinded. In a randomized trial performed at the
University of Kentucky [6], 48 patients with known sys-
temic cancer were treated with either biopsy of the sus-
pected brain metastasis plus WBRT or complete surgical
resection of the metastasis plus WBRT. The radiation doses
were the same in both groups and consisted of a total dose
of 36 Gy given in 12 daily fractions of 3 Gy each. Patients
had to be capable of caring for themselves independently,
with a Karnofsky performance score (KPS) of at least 70.
Patients were ineligible if they had a need for immediate
treatment to prevent acute neurologic deterioration, or if
they had tumors considered to be relatively radiosensitive
[small cell lung cancer (SCLC), germ-cell tumors, lym-
phoma, leukemia, and multiple myeloma]. Patients were
not excluded based on the extent of systemic disease.
Randomization was performed by computer-generated
random numbers. Information on allocation concealment
was not reported. All the patients in the surgical group
were considered to have had complete resection as assessed
by postoperative computerized tomography (CT) scanning.
Follow up brain CT or magnetic resonance imaging (MRI)
scans were required every 3 months. There was a statisti-
cally signiﬁcant increase in survival in the surgical group
(40 vs. 15 weeks). In addition, the time to recurrence of
brain metastases, freedom from death due to neurologic
causes, and duration of functional independence were
signiﬁcantly longer in the surgical resection group. The
1 month mortality was 4% in each group, indicating that
there was no extra mortality from surgery. Although sur-
gical resection was the only variable positively associated
with maintaining performance status, the extent of systemic
disease and increased age were associated with poor per-
formance status post-treatment.
A second randomized study [8], conducted as a multi-
institutional trial in the Netherlands, contained 63 evalu-
able patients. Patients with single brain metastases were
randomized to complete surgical resection plus WBRT or
WBRT alone. Randomization was performed centrally by
telephone. The WBRT schedules were the same for both
treatment arms and consisted of 40 Gy given in a non-
standard fractionation scheme of 2 Gy twice per day for
2 weeks (10 treatment days). Patients had to have a rea-
sonable quality of life and neurological status, deﬁned as
spending no more than 50% of their time in bed and not
requiring continuous nursing care or hospitalization.
Excluded histologies were SCLC and lymphoma. Infor-
mation is not given regarding the extent of resection in the
surgical group or the use and frequency of imaging in
follow up. Survival was signiﬁcantly longer in the surgical
group (10 vs. 6 months). There was also a non-signiﬁcant
trend toward longer duration of functional independence in
the surgically treated patients. No data concerning recur-
rence of brain metastases were provided. The 1 month
mortality rates were 9% in the surgery group and 0% in the
WBRT alone group, a statistically insigniﬁcant difference.
The authors concluded that the addition of surgery to
WBRT provided a survival beneﬁt except to those patients
who were 60 years of age or older, or those patients with
progressive systemic disease in the 3 months prior to the
diagnosis of the brain metastasis.
A third randomized trial, conducted as a multi-center
trial in Canada by Mintz et al. [7], failed to ﬁnd a beneﬁt
from surgical treatment. In that study, 84 patients with a
single brain metastasis were randomized to receive radio-
therapy alone (30 Gy given in 10 daily fractions of 3 Gy)
or surgery plus radiotherapy. Randomization was per-
formed centrally by telephone. Eligible patients had to be
less than 80 years of age, and they had to have a KPS of at
least 50, i.e., they could be spending more than 50% of
their time in bed but had to be able to care for some per-
sonal needs. Patients were not eligible if they had leuke-
mia, lymphoma, or SCLC. A CT scan was done in the ﬁrst
postoperative week to assess the extent of tumor removed.
Follow up CT scans were performed monthly for 6 months
and every 3 months after that. A gross total resection was
achieved in 38 of the 40 patients in the surgical group. No
difference was found in overall survival; the median sur-
vival time was 6.3 months in the radiotherapy alone group
and 5.6 months for the surgical group. There was also no
difference in causes of death or quality of life.
It is unclear why the Canadian study was not in agree-
ment with the other two trials. In all three studies, the
control arms (the radiation alone arms) had median lengths
of survival in the 3–6 months range—within the expected
range for patients treated with radiotherapy alone. The
major difference in the studies was the poor results
obtained in the surgical arm of the Canadian trial. That
study contained a higher proportion of patients with
extensive systemic disease and lower performance scores.
It is possible that these factors resulted in more patients
dying of their systemic cancer before a long term beneﬁt of
surgery was seen. Additionally, MRI was not mandatory in
the Canadian study, and it is theoretically possible that
patients with additional lesions not detected by CT may
have been included in the study.
All three of the evidence class II studies [9–11] dem-
onstrated a survival beneﬁt for patients who underwent
surgical resection followed by WBRT as compared to
J Neurooncol (2010) 96:17–32 21
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123WBRT alone. Ampil et al., published a single institution
experience with either surgery plus WBRT (11 patients)
versus WBRT alone (34 patients) in 45 patients who had a
cerebellar metastasis. The majority of the patients in the
WBRT alone arm had additional supratentorial brain
metastases. Although there was a signiﬁcant difference in
survival noted between the two groups, the authors con-
cluded that the outcome of patients with a brain metastasis
within the cerebellum was improved with surgical resec-
tion if the primary was not from the lung.
WBRT dosing/fractionation schedule
Twenty-three studies met the eligibility criteria for this
question, and of these, 17 were unique [12–28] and six [31–
36] were companion publications (Table 2). The 17 unique
studies fell into three AANS/CNS evidence class categories
as follows: ten class I studies (nine RCTs [12–20] and one
randomized phase I/II trial [21]), six class II studies [22–24,
26–28] (retrospective cohort studies) and one class III study
[25] (prospective cohort study with historical controls).
The radiation dosages have been expressed in terms of
the tumor response biologically effective dose (BED) in
order to quantitatively capture the observed biological
effect between treatment arms. This was calculated from
the linear quadratic equation:BED ¼ nd 1 þ d=ða=bÞ ½ 
where n = number of treatments, d = dose per fraction;
the calculation assumes a/b = 10 Gy for tumor effects of
each schedule, however it is uncorrected for treatment
regimes of two fractions/day. The BED units are referred to
in terms of Gy10 to indicate that the BED values are single-
point calculations for tumor response [37, 38] and no
correction for accelerated repopulation was made.
Expressing radiation dosages in terms of the BED takes
into account the total dose of radiation, fraction size, and
overall time to deliver the radiation, and presumed repair of
irradiated tissue. The analyses are stratiﬁed by low or high
dose versus control dose. The control group consists of
patients treated with 30 Gy in 10 fractions for a BED = 39
Gy10 (therefore assigning the low dose regimens as a BED
\39 Gy10, and high dose regimens as a BED[39 Gy10).
None of the trials demonstrated a meaningful improve-
ment in any endpoint relative to dose; speciﬁcally, survival
was not improved. There was considerable overlap in terms
of survival even at the same dose level in different trials,
underscoring the signiﬁcance of host-speciﬁc variables in
determining survival.
The data from the randomized trials, stratiﬁed by the
BED are shown in Table 3.
The meta-analyses were stratiﬁed by low or high dose
versus control dose. Studies lacking a comparable control
were excluded from meta-analyses, due to the inherent
dosing variability amongst the study’s control group.
Figure 2 indicates the RR of mortality at 6 months in the
low dose (BED\39 Gy10) group compared to that in the
WBRT control group (BED = 39 Gy10). Only data from
two trials (Chantani et al. [13] and Priestman et al. [20])
were robust enough to be considered for this end-point.
When combined, no difference (P = 0.52) was found for
6 month mortality (RR 1.05; 95% CI 0.90, 1.23). Figure 3
presents the same analysis, but for the comparison of the
high dose (BED[39 Gy10) group to the WBRT control
group (BED = 39 Gy10). Data from ﬁve trials were robust
enough to be considered for this end-point. Combining data
for Chantani et al. [13, 14], Komarnicky et al. [17], Kurtz
et al. [18], and Murray et al. [19], yielded no difference
(P = 0.39) in 6 month mortality (RR 1.05; 95% CI 0.94,
1.18). A 1981 trial by Borgelt et al. [12] was excluded from
the meta-analyses for lack of a comparable control. Since
the administered dosage ranged from 20 to 40 Gy over 1–
4 weeks, the resulting permutations and combinations of
plausible radiation schedules in this group varied too sub-
stantially (22–72 Gy10) to function as a true control. The
inherent dosing variability disqualiﬁed this control group
thereby making the trial ineligible for comparison.
Similar comparisons were made for overall survival and
neurologic function, and no dose–effect was identiﬁed for
either end-point. Figures 4 and 5 depict the overall survival
for the respective comparisons of low and high BED values
versus the control BED. In Fig. 4, the pooling of two
studies, Chantani et al. [13] and Priestman et al. [20], for
the comparison of low dose WBRT (BED\39 Gy10)t oa
control dose (BED = 39 Gy10) yielded no difference
(P = 0.07) in overall survival (RR 0.86; 95% CI 0.73,
1.01). In Fig. 5, overall survival data from Chantani et al.
[13, 14], Komarnicky et al. [17], Kurtz et al. [18], and
Murray et al. [19], were pooled for the comparison of high
dose WBRT (BED[39Gy10) versus WBRT control dose
(BED = 39 Gy10). No difference (P = 0.26) in overall
survival was found (RR 1.06; 95% CI 0.96, 1.18). The
hazard plots for neurologic function are not presented.
Impact of tumor histopathology on WBRT treatment
outcomes
Using the AANS/CNS evidence classiﬁcation, no papers
with class I or II evidence were identiﬁed by the systematic
literature review that met the eligibility criteria for this
question. In fact, only one paper, providing class III evi-
dence, met the inclusion criteria (Table 4). The only data is
provided by a single institution retrospective analysis with
75 cases (Sundstrom et al. [29]). In that study, there were
15 cases that were of classic ‘‘radio-resistant’’ histology.
There were no statistically signiﬁcant differences in overall
survival by tumor histology. Local control by tumor type
was not reported.
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123Conclusion
Surgical resection plus WBRT versus WBRT alone
Based on the available class I and class II evidence, sur-
gical resection followed by WBRT is an effective treatment
for patients with single, surgically accessible, brain
metastases who have controlled extra-cranial disease and
are in good general condition. Good general condition in
the relevant studies was deﬁned as functional independence
and spending less than 50% of time in bed. Patients with
disease progression in the 3 months preceding the diag-
nosis of the brain metastases have a relatively poor survival
and poor functional status but still had a signiﬁcant
improvement in survival as a result of surgical resection.
Due to the risk of fourth ventricle compression and the
Table 3 Randomized trials
stratiﬁed by the BED for
different treatment schedules
a Treatment regimes of two
fractions/day (BED
uncorrected)
Author Year Total
dose (Gy)
Fractions BED (Gy;
a/b = 10)
n Median survival
(weeks)
Borgelt 1981 12 2 19.2 33 13
Priestman 1996 12 2 19.2 270 11
Borgelt 1981 10 1 20 26 15
Borgelt 1981 20 5 28 31 12
Chatani 1994 20 5 28 35 10.4
Davey 2008 20 5 28 45 19.1
Haie-Meder 1993 18 3 28.8 110 18.3
Chatani 1994 30 10 39 46 23.5
Chatani 1994 30 10 39 35 14.8
Chatani 1985 30 10 39 35 17.4
Komarnicky 1991 30 10 39 193 19.5
Komarnicky 1991 30 10 39 190 16.9
Kurtz 1981 30 10 39 130 18.2
Murray 1997 30 10 39 213 19.6
Priestman 1996 30 10 39 263 12
Komarnicky 1991 30 6 45 200 17.8
Komarnicky 1991 30 6 45 196 13.5
Davey 2008 40 20
a 48 45 19.1
Sause 1993 48 30
a 55.7 62 18.3
Haie-Meder 1993 – – 50.8 106 23
Chatani 1994 50 20 62.5 46 20.9
Chatani 1985 50 20 62.5 34 13
Kurtz 1981 50 20 62.5 125 16.9
Murray 1997 54.4 34
a 63.1 216 19.6
Sause 1993 54.4 34
a 63.1 115 22.6
Sause 1993 64 40
a 74.2 104 20.9
Sause 1993 70.4 44
a 81.7 53 27.8
Borgelt 1981 30–40 10–20 34.5–56 112 21
Study or Subgroup
Chatani 1994
Priestman 1996
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 1.84, df = 1 (P = 0.18); I² = 46%
Test for overall effect: Z = 0.64 (P = 0.52)
Events
27
224
251
Total
35
270
305
Events
29
197
226
Total
35
263
298
Weight
29.5%
70.5%
100.0%
M-H, Random, 95% CI
0.93 [0.74, 1.18]
1.11 [1.01, 1.21]
1.05 [0.90, 1.23]
o i t a R   k s i R o i t a R   k s i R e s o d   l o r t n o C e s o d   w o L
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours low dose Favours control dose
Fig. 2 Comparison of low dose WBRT (BED\39 Gy10) versus WBRT control dose (BED = 39 Gy10): mortality at 6 months
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123subsequent increase in intracranial pressure, surgery should
be particularly considered if there is a brain metastasis
situated within the posterior fossa.
Surgical resection plus WBRT versus surgical resection
alone
The surgical resection guideline paper by Kalkanis et al.
[1] outlines in detail the evidence supporting the addition
of WBRT after surgical resection. Please refer to this paper
for a further discussion of why the combined modalities of
surgical resection followed by WBRT represent a superior
treatment option, in terms of improving tumor control at
the original site of the metastasis and in the brain overall,
when compared to surgical resection alone
If WBRT is used, is there an optimal dosing/
fractionation schedule?
There is class I evidence that altered dose/fractionation
schedules of WBRT do not result in signiﬁcant differences
in median survival, local control or neurocognitive function
when compared to ‘‘standard’’ WBRT dose/fractionation.
(i.e., 30 Gy in 10 daily fractions or a BED of 39 Gy10).
If WBRT is used, what impact does tumor
histopathology have on treatment outcomes?
Only one small case series (class III evidence) met the
eligibility criteria for the question addressing the impact of
histopathology on WBRT treatment outcomes. Further
Study or Subgroup
Chatani 1985
Chatani 1994
Komarnicky 1991
Kurtz 1981
Murray 1997
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.01; Chi² = 6.88, df = 4 (P = 0.14); I² = 42%
Test for overall effect: Z = 0.86 (P = 0.39)
Events
29
27
132
99
136
423
Total
34
46
216
153
216
665
Events
20
25
138
98
128
409
Total
35
46
212
156
213
662
Weight
10.6%
8.8%
28.4%
24.7%
27.6%
100.0%
M-H, Random, 95% CI
1.49 [1.08, 2.05]
1.08 [0.75, 1.55]
0.94 [0.81, 1.09]
1.03 [0.87, 1.22]
1.05 [0.90, 1.22]
1.05 [0.94, 1.18]
o i t a R   k s i R o i t a R   k s i R e s o d   l o r t n o C e s o d   h g i H
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Fig. 3 Comparison of high dose WBRT (BED[39 Gy10) versus WBRT control dose (BED = 39 Gy10): mortality at 6 months (Note:
extraction of data for Komarnicky trial is based on the K–M curve)
Study or Subgroup
Chatani 1985
Chatani 1994
Komarnicky 1991
Kurtz 1981
Murray 1997
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.82, df = 4 (P = 0.43); I² = 0%
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Fig. 5 Comparison of high dose WBRT (BED[39 Gy10) versus WBRT control dose (BED = 39 Gy): overall survival
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Fig. 4 Comparison of low dose WBRT (BED\39 Gy10) versus WBRT control dose (BED = 39 Gy10): overall survival
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123Table 4 Study evaluating WBRT treatment outcome by histopathology
First author (year): Sundstro ¨m (1998) [29]
Study characteristics Study outcomes Study quality
Study design: case series Primary outcome: survival Quality assessment: N/A as non-
comparative study
Inclusion criteria:
Pts treated with WBRT for BM diagnosed by CT or
MRI
Minimum midline dose to the whole brain of at least
25 Gy
Median survival by primary tumor type:
Breast: 7 months (range 1–62 months)
Lung: 4 months (range 1–21 months)
Renal cell: 4 months (range 2–34 months)
Melanoma: 3 months (range 1–6 months)
Other primaries: 4 months (range 1–9 months)
(Survival curves: P-value not reported)
AANS/CNS evidence classiﬁcation:
class III
Interventions:
WBRT [mean dose 30 Gy (range 25–40 Gy) in 1.8–
3 Gy fractions]
Tumor control: not reported
Median follow-up: not reported
# Male:
Breast: 0/19, lung: 26/35, renal cell: 4/9, melanoma:
6/6, other: 6/6
Median time to recurrence of brain metastases:
not reported
Median age (range):
Breast: 53 years (39–77 years)
Lung: 64 years (43–78 years)
Renal cell: 61 years (41–69 years)
Melanoma: 61 years (39–62 years)
Other: 61 years (50–71 years)
Functional performance: not reported by
histology
Cause of death: not reported
Adverse events: not reported by tumor type
# Of brain metastases:
Breast: 1 BM 9/19, 2 BM 4/19,[2 BM 6/19
Lung: 1 BM 15/35, 2 BM 5/35,[2 BM 15/35
Renal cell: 1 BM 3/9, 2 BM 2/9,[2 BM 4/9
Melanoma: 1 BM 3/6, 2 BM 0/6,[2 BM 3/6
Other: 1 BM 3/6, 2 BM 2/6,[2 BM 1/6
Extra-cranial disease: Extra-cranial metastases:
Breast: 17/19
Lung: 6/35
Renal cell: 5/9
Melanoma: 4/6
Other: 5/6
Baseline functional performance:
WHO classiﬁcation (0 (best) to 4 (worst)
Performance status (PS):
Breast: PS 0–1 9/19, PS 2 5/19, PS 3 5/19
Lung: PS 0-1 10/35, PS 2 16/35, PS 3 9/35
Renal cell: PS 0–1 2/9, PS 2 5/9, PS 3 2/9
Melanoma: PS 0–1 6/6
Other: PS 0–1 3/6, PS 2 1/6, PS 3 2/6
AANS American Association of Neurological Surgeons, BM brain metastases, CNS Congress of Neurological Surgeons, CT computed tomog-
raphy, MRI magnetic resonance imaging, NA not available, Pts patients, WBRT whole brain radiation therapy, WHO World Health Organization
30 J Neurooncol (2010) 96:17–32
123studies in this area are needed before any recommendations
can be made.
Key issues for future investigation
There have been numerous studies comparing various dose/
fractionation schemes for WBRT. Unless future studies
incorporate more sophisticated measures of neurocognitive
outcome there is little need to repeat these studies. There
are, however, very few studies evaluating the effectiveness
of WBRT for one histopathological type versus another.
Future studies of WBRT explicitly addressing treatment
outcomes for well-deﬁned patient groups by different
tumor types are needed.
The following is a list of major ongoing or recently
closed randomized trials pertaining to the use of whole
brain radiation therapy that evaluate treatment comparisons
addressed by this guideline paper for the management of
newly diagnosed brain metastases.
1. Brain metastases study: radiotherapy schemes in the
treatment of brain metastases
Ofﬁcial Title: To determine which of two radiotherapy
brain fractionation schemes is superior in the treatment
of brain metastases
Status: Completed
Clinicaltrials.gov Identiﬁer: NCT00138788
Principal Investigator: Associate Professor, Peter H
Graham, Cancer Care Centre, St George Hospital
Location: Australia
Sponsors and Collaborators: St George Hospital,
Australia
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